SEC Form 4 · accession 0001209191-17-044264
Dova Pharmaceuticals Inc. · DOVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kevin Laliberte
Officer — Sr. VP, Product Development
Period of report
Jul 5, 2017
Accepted (ET)
Jul 7, 2017 · 6:47 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001685071
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 5, 2017 | P | 6,200 | $17.00 | A | 6,200 | D |
Table II — derivative securities
No Table II lines on this filing.